Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas
| Autor: | Tao Jiang, Guilin Li, Kaijia Zhou, Wei Zhang, Tianzi Jiang, Xiaoguang Qiu, Li Xu, Yi Lin, Baoshi Chen, Sonya W. Song |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Enzyme-Linked Immunosorbent Assay Kaplan-Meier Estimate Preoperative care Gastroenterology Disease-Free Survival Neurosurgical Procedures Internal medicine Glioma Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Grade II Glioma Humans neoplasms Retrospective Studies Brain Neoplasms business.industry Proportional hazards model Hazard ratio Prognosis medicine.disease Combined Modality Therapy Immunohistochemistry Confidence interval nervous system diseases Insulin-Like Growth Factor Binding Protein 2 Treatment Outcome Oncology Chemotherapy Adjuvant Basic and Translational Investigations Biomarker (medicine) Population study Female Neurology (clinical) Neoplasm Recurrence Local business |
| Zdroj: | Neuro-Oncology. 11:468-476 |
| ISSN: | 1523-5866 1522-8517 |
| Popis: | Insulin-like growth factor binding protein 2 (IGFBP-2) is a malignancy-associated protein measurable in tumors and blood. Increased IGFBP-2 is associated with shortened survival of advanced glioma patients. Thus, we examined plasma IGFBP-2 levels in glioma patients and healthy controls to evaluate its value as a plasma biomarker for glioma. Plasma IGFBP-2 levels in 196 patients with newly diagnosed glioma and 55 healthy controls were analyzed using an IGFBP-2 ELISA kit. Blood was collected before surgery, after two-cycle adjuvant chemotherapy, and at recurrence. Plasma IGFBP-2 levels were correlated with disease-free survival DFS) using Cox regression analyses. We found that preoperative plasma IGFBP-2 levels were significantly higher in high-grade glioma patients n = 43 for grade III glioma; n = 72 for glioblastoma multiforme [GBM]) than in healthy controls n = 55; p < 0.001) and low-grade (grade II) glioma patients n 5 81; p, 0.001). No significant differences in preoperative plasma IGFBP-2 levels were observed between grade III glioma and GBM patients or between grade II glioma patients and healthy controls. After recurrence, plasma IGFBP-2 levels were significantly increased in GBM patients (n = 26; p < 0.001). Preoperative plasma IGFBP-2 levels were significantly correlated with DFS in GBM patients ( hazard ratio, 1.404; 95% confidence interval, 1.078-1.828; p = 0.012). We conclude that preoperative plasma IGFBP-2 levels are significantly higher in high-grade glioma patients than in low-grade glioma patients and healthy subjects, and are significantly correlated with recurrence and DFS in patients with GBM. Longitudinal studies with a larger study population are needed to confirm these findings. Neuro-Oncology 11, 468-476, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00199, January 22, 2009. URL http://neuro-oncology. dukejournals. org; DOI: 10.1215/15228517-2008-114) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|